SC
WHWK

Stempoint Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Stempoint Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.24M Sell
939,369
-519,438
-36% -$1.63M 0.62% 45
2025
Q4 		$3.53M Buy
1,458,807
+1,034,725
+244% +$2.37M 0.61% 47
2025
Q3 		$806K Buy
+424,082
New +$780K 0.16% 68

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Stempoint Capital's WHWK Position: Q1 2026 in Review

Stempoint Capital reduced its Whitehawk Therapeutics (WHWK) stake by 36% in Q1 2026, selling an estimated $1.63M and leaving 939,369 shares worth $3.24M. The position accounts for 0.62% of the portfolio, ranked #45.

Stempoint Capital first reported a position in WHWK in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.53M in Q4 2025. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Stempoint Capital held 939,369 shares of Whitehawk Therapeutics worth $3.24M as of Q1 2026.
  • Stempoint Capital sold 519,438 Whitehawk Therapeutics shares in Q1 2026, an estimated $1.63M.
  • Whitehawk Therapeutics made up 0.62% of Stempoint Capital's portfolio in Q1 2026, its #45 holding.
  • Stempoint Capital first reported a position in Whitehawk Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Stempoint Capital's Whitehawk Therapeutics position peaked at $3.53M in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.